EA201101116A1 - Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина - Google Patents

Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина

Info

Publication number
EA201101116A1
EA201101116A1 EA201101116A EA201101116A EA201101116A1 EA 201101116 A1 EA201101116 A1 EA 201101116A1 EA 201101116 A EA201101116 A EA 201101116A EA 201101116 A EA201101116 A EA 201101116A EA 201101116 A1 EA201101116 A1 EA 201101116A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxo
pharmaceutical compositions
pyrrolidine derivatives
pyrrolidine
derivatives
Prior art date
Application number
EA201101116A
Other languages
English (en)
Other versions
EA022057B1 (ru
Inventor
Серж Кюйпер
Моник Бервар
Доменико Фанара
Валери Барийаро
Original Assignee
Юсб Фарма, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Фарма, С.А. filed Critical Юсб Фарма, С.А.
Publication of EA201101116A1 publication Critical patent/EA201101116A1/ru
Publication of EA022057B1 publication Critical patent/EA022057B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

В заявке описан состав фармацевтических соединений с немедленным высвобождением.
EA201101116A 2009-01-29 2010-01-27 Фармацевтические композиции, включающие бриварацетам EA022057B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09100083 2009-01-29
PCT/EP2010/050892 WO2010094535A1 (en) 2009-01-29 2010-01-27 Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

Publications (2)

Publication Number Publication Date
EA201101116A1 true EA201101116A1 (ru) 2012-03-30
EA022057B1 EA022057B1 (ru) 2015-10-30

Family

ID=40622206

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101116A EA022057B1 (ru) 2009-01-29 2010-01-27 Фармацевтические композиции, включающие бриварацетам

Country Status (23)

Country Link
US (2) US10729653B2 (ru)
EP (1) EP2391349B1 (ru)
JP (1) JP5576401B2 (ru)
KR (1) KR101640164B1 (ru)
CN (2) CN102292071B (ru)
AU (1) AU2010215646B2 (ru)
BR (1) BRPI1007161B1 (ru)
CA (1) CA2747395C (ru)
CY (1) CY1115673T1 (ru)
DK (1) DK2391349T3 (ru)
EA (1) EA022057B1 (ru)
ES (1) ES2511047T3 (ru)
HK (2) HK1161988A1 (ru)
HR (1) HRP20141006T1 (ru)
IL (1) IL213545A (ru)
ME (1) ME01927B (ru)
MX (1) MX2011007267A (ru)
PL (1) PL2391349T3 (ru)
PT (1) PT2391349E (ru)
RS (1) RS53554B1 (ru)
SI (1) SI2391349T1 (ru)
SM (1) SMT201400155B (ru)
WO (1) WO2010094535A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011007451A (es) * 2009-01-29 2011-08-03 Ucb Pharma Sa Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
CN104800176A (zh) * 2015-04-23 2015-07-29 广东赛烽医药科技有限公司 一种布瓦西坦口崩片及其制备方法
BR112018012870A2 (pt) 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc métodos e composições para o tratamento de transtornos relacionados à crise
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
US20190054027A1 (en) * 2017-08-18 2019-02-21 Abbvie Inc. Solid Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis
CN109833300A (zh) * 2017-11-28 2019-06-04 浙江京新药业股份有限公司 一种抗癫痫药物口服组合物及其制备方法
EP3781167A4 (en) 2018-04-19 2022-02-23 Abbvie Inc. METHOD OF TREATMENT OF HEAVY MENSTRUAL BLEEDING
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
CN113288872A (zh) * 2020-02-21 2021-08-24 广东东阳光药业有限公司 一种2-吡咯烷酮衍生物的组合物及其制备方法
CN112933059A (zh) * 2021-03-25 2021-06-11 浙江昂利康制药股份有限公司 一种布立西坦片剂的干法制粒工艺
CN115192572B (zh) * 2021-04-08 2023-09-19 成都同道慧宜生物医药科技有限公司 布立西坦药剂、其制备方法和应用
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595761A (en) * 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
GEP20053654B (en) * 2001-05-01 2005-11-10 Pfizer Prod Inc Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution
JP2005298338A (ja) 2002-02-27 2005-10-27 Eisai Co Ltd 速崩壊性圧縮成形製剤
CN1186094C (zh) * 2002-07-01 2005-01-26 蔡海德 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法
US7799538B2 (en) * 2005-03-09 2010-09-21 Trustees Of Dartmouth College Method for identifying agents which modulate GTPase activity involved in insulin-stimulated GLUT4 translocation
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
US8802142B2 (en) * 2005-07-26 2014-08-12 Ucb Pharma, S.A. Pharmaceutical compositions comprising levetiracetam and process for their preparation
BRPI0712325A2 (pt) * 2006-06-08 2012-01-10 Ucb Pharma Sa processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal
EP2056792B1 (en) 2006-08-31 2023-06-07 Adare Pharmaceuticals, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs
TW200836747A (en) * 2007-01-05 2008-09-16 Combinatorx Inc Methods, compositions, and kits for the treatment of pain
MX2011007451A (es) * 2009-01-29 2011-08-03 Ucb Pharma Sa Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.

Also Published As

Publication number Publication date
MX2011007267A (es) 2011-08-15
AU2010215646A1 (en) 2011-08-04
CN104083328A (zh) 2014-10-08
BRPI1007161B1 (pt) 2022-03-22
EP2391349B1 (en) 2014-07-23
DK2391349T3 (da) 2014-11-03
JP2012516302A (ja) 2012-07-19
EP2391349A1 (en) 2011-12-07
ME01927B (me) 2015-05-20
HK1198287A1 (en) 2015-03-27
US20110281929A1 (en) 2011-11-17
PT2391349E (pt) 2014-10-27
JP5576401B2 (ja) 2014-08-20
CN104083328B (zh) 2017-04-12
PL2391349T3 (pl) 2014-12-31
EA022057B1 (ru) 2015-10-30
HRP20141006T1 (hr) 2014-12-19
WO2010094535A1 (en) 2010-08-26
KR20120008022A (ko) 2012-01-25
CY1115673T1 (el) 2017-01-25
CN102292071A (zh) 2011-12-21
US10729653B2 (en) 2020-08-04
IL213545A (en) 2016-05-31
RS53554B1 (en) 2015-02-27
ES2511047T3 (es) 2014-10-22
CA2747395C (en) 2015-01-13
CN102292071B (zh) 2016-08-24
SMT201400155B (it) 2015-01-15
SI2391349T1 (sl) 2014-12-31
KR101640164B1 (ko) 2016-07-15
US20120108464A1 (en) 2012-05-03
IL213545A0 (en) 2011-07-31
BRPI1007161A2 (pt) 2016-02-23
HK1161988A1 (zh) 2012-08-17
AU2010215646B2 (en) 2014-03-27
CA2747395A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
ECSP10010722A (es) Compuestos orgánicos
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
BRPI0915084B8 (pt) composto, e, composição farmacêutica
DK2345410T3 (da) Farmaceutisk sammensætning til modificeret frigivelse
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2010119455A3 (en) An injectable sustained release pharmaceutical composition
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
TN2009000510A1 (en) Extended release formulation of nevirapine
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment